 Connection
Manali Kamdar to Immunotherapy, Adoptive
This is a "connection" page, showing publications Manali Kamdar has written about Immunotherapy, Adoptive.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
4.888 |
|
|
|
-
Hunter BD, Lunning M, Shadman M, Ahmed S, Abramson JS, Perales MA, Ahmed N, Mirza AS, Isufi I, Frigault MJ, Crombie JL, Miklos DB, Vasconcelos A, Crotta A, Bernasconi D, Roy D, Bleickardt E, Pasquini MC, Kamdar M. CRS or ICANS Are Rare Beyond 2 Weeks After Lisocabtagene Maraleucel Infusion: Data From Clinical Trials and the Real-World Setting. Transplant Cell Ther. 2026 Feb; 32(2):171.e1-171.e12.
Score: 0.709
-
Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers P, Hernandez-Ilizaliturri F, Izutsu K, Morschhauser F, Lunning M, Chow VA, Montheard S, Santamaria J, Colicino S, Ogasawara K, Stepan L, Liu FF, Abramson JS. Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study. J Clin Oncol. 2025 08 20; 43(24):2671-2678.
Score: 0.694
-
Colton M, Purev E, Haverkos B, Bair S, Jasem J, Jacob A, Kamdar M. Molecular Disease Monitoring in Patients With Relapsed/refractory B-Cell Lymphoma Receiving Anti-CD19 CAR T-Cell Therapy. Clin Lymphoma Myeloma Leuk. 2024 Nov; 24(11):778-782.
Score: 0.647
-
Kamdar M, Bartlett NL. From breakthroughs to blueprints: evolving evidence and future directions in relapsed and refractory large B-cell lymphoma. Blood. 2026 Jun 11; 147(24):2879-2894.
Score: 0.185
-
Sharp J, Strati P, Bhatta S, Huang JJ, Thomas C, Elghawy O, Reef D, Gorzewski A, Wang J, Shouse G, Reinert C, Teferra A, Velez ET, Pelcovits A, Ollila T, Clark W, Yazbeck V, Maakaron J, Kamdar M, Fitzgerald L, Danilov A, Karmali R, Grover NS, Barta SK, Voorhees TJ, Chen AI, Shadman M, Ahmed S, Epperla N. Real-world outcomes and toxicities of CAR-T in relapsed/refractory follicular lymphoma: a multicenter cohort study. Blood Adv. 2026 Jun 09; 10(11):3757-3768.
Score: 0.185
-
Palomba ML, Schuster SJ, Karmali R, Skarbnik AP, Abramson JS, Ardeshna K, Borchmann P, Hill BT, García-Sancho AM, Marcacci G, Rapoport AP, Cartron G, Fleury I, Izutsu K, Kamdar M, Mielke S, Barbui AM, Ortega JLR, Nastoupil LJ, Ahmed S, Bar M, Diaz L, Furustrand U, Diab V, Vedal M, Avilion A, Kumar J, Nishii R, Colicino S, Morschhauser F. Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study. Lancet. 2026 Mar 07; 407(10532):963-975.
Score: 0.181
-
Epstein-Peterson ZD, Lionel AC, Joseph A, Drill E, Atallah-Yunes SA, Brooks TR, Chong EA, Chong ER, Dela Cruz J, Frank MJ, Ip A, Iqbal M, Jacobson CA, Kamdar MK, Karmali R, Beyar-Katz O, Maddocks KJ, Matasar MJ, McLoughlin D, Merryman RW, Munoz JL, Navalekar R, Rhodes J, Riedell PA, Ryan CE, Salles G, Sauter CS, Sawalha Y, Sharma S, Shouval R, Shukla N, Therwhanger D, van Besien H, Varon B, Wang Y, Yamshon S, Zelenetz AD, Palomba ML, Jain P, Kumar A. Treatment and outcomes of progression of disease post-CAR T-cell therapy in mantle cell lymphoma: a multicenter analysis. Blood Adv. 2025 Nov 11; 9(21):5654-5662.
Score: 0.178
-
Shadman M, Ahmed S, Byrne MT, Chavez JC, Kamdar M, Sorror ML, Perales MA, Hill JA, Moslehi J, Miklos DB. Who Is Eligible for Chimeric Antigen Receptor T Cell Therapy? Expert Perspectives on Overcoming Referral Barriers. Transplant Cell Ther. 2026 Mar; 32(3):277-287.
Score: 0.177
-
Abramson JS, Kamdar M, Liu FF, Crotta A, Previtali A, Klijn SL, Wang P, Zhang Y, Bonner A, Lunning M. Matching-adjusted indirect comparison of lisocabtagene maraleucel versus axicabtagene ciloleucel for second-line treatment of patients with early relapsed or refractory large B-cell lymphoma. Leuk Lymphoma. 2025 Dec; 66(12):2200-2213.
Score: 0.174
-
Samples L, Sadrzadeh H, Frigault MJ, Jacobson CA, Hamadani M, Gurumurthi A, Strati P, Shouval R, Noy A, Riedell PA, Dahiya S, Maloney DG, Till BG, Hirayama AV, Gauthier J, Gopal AK, Smith SD, Poh C, Lynch R, Ujjani C, Di M, Raghunathan V, Shakib-Azar M, Naresh KN, Gooley TA, Yared J, Jain MD, Locke FL, Leslie LA, Epperla N, Ghosh M, Skarbnik A, Hill BT, Kamdar MK, Ortiz-Maldonado V, Martinez-Cibrian N, Shune L, Shadman M. Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma. Blood. 2025 Jun 05; 145(23):2762-2767.
Score: 0.173
-
Kamdar M. CARs to the rescue: rare aggressive lymphoma gets a power up. Blood Adv. 2024 10 22; 8(20):5342-5343.
Score: 0.165
-
Morschhauser F, Dahiya S, Palomba ML, Martin Garcia-Sancho A, Reguera Ortega JL, Kuruvilla J, Jäger U, Cartron G, Izutsu K, Dreyling M, Kahl B, Ghesquieres H, Ardeshna K, Goto H, Barbui AM, Abramson JS, Borchmann P, Fleury I, Mielke S, Skarbnik A, de Vos S, Kamdar M, Karmali R, Viardot A, Farazi T, Fasan O, Lymp J, Vedal M, Nishii R, Avilion A, Papuga J, Kumar J, Nastoupil LJ. Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study. Nat Med. 2024 08; 30(8):2199-2207.
Score: 0.161
-
Major A, Kamdar M. Selection of bispecific antibody therapies or CAR-T cell therapy in relapsed lymphomas. Hematology Am Soc Hematol Educ Program. 2023 12 08; 2023(1):370-381.
Score: 0.156
-
Shouse G, Kaempf A, Gordon MJ, Artz A, Yashar D, Sigmund AM, Smilnak G, Bair SM, Mian A, Fitzgerald LA, Bajwa A, Jaglowski S, Bailey N, Shadman M, Patel K, Stephens DM, Kamdar M, Hill BT, Gauthier J, Karmali R, Nastoupil LJ, Kittai AS, Danilov AV. A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma. Blood Adv. 2023 07 25; 7(14):3516-3529.
Score: 0.152
-
Sureda A, Lugtenburg PJ, Kersten MJ, Subklewe M, Spanjaart A, Shah NN, Kerbauy LN, Roddie C, Pennings ERA, Mahuad C, Poon M, Hendricks CL, Kamdar M, Jacobson C. Cellular therapy in lymphoma. Hematol Oncol. 2024 Nov; 42(6):e3200.
Score: 0.151
-
Abramson JS, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers P, Hernandez-Ilizaliturri F, Izutsu K, Morschhauser F, Lunning M, Crotta A, Montheard S, Previtali A, Ogasawara K, Kamdar M. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood. 2023 04 06; 141(14):1675-1684.
Score: 0.148
-
Duarte C, Kamdar M. Management Considerations for Patients With Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma. Am Soc Clin Oncol Educ Book. 2023 Jan; 43:e390802.
Score: 0.146
-
Jodon G, Colton MD, Abbott D, Cai A, Haverkos B, Morgan R, Kamdar M. Clinical and Radiographic Predictors of Progression and Survival in Relapsed/Refractory Lymphoma Patients Receiving Anti-CD19 CAR T-cell Therapy. Clin Lymphoma Myeloma Leuk. 2023 01; 23(1):49-56.
Score: 0.143
-
Pasquini MC, Hu ZH, Curran K, Laetsch T, Locke F, Rouce R, Pulsipher MA, Phillips CL, Keating A, Frigault MJ, Salzberg D, Jaglowski S, Sasine JP, Rosenthal J, Ghosh M, Landsburg D, Margossian S, Martin PL, Kamdar MK, Hematti P, Nikiforow S, Turtle C, Perales MA, Steinert P, Horowitz MM, Moskop A, Pacaud L, Yi L, Chawla R, Bleickardt E, Grupp S. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020 11 10; 4(21):5414-5424.
Score: 0.126
-
Alderuccio JP, Baggio D, Han S, Ghione P, Nizamuddin I, Khwaja J, Saha A, Dong N, Wang Y, Cherng HJ, Tolu S, Wagner-Johnston N, Ollila TA, Grover N, Koff JL, Desai A, Ramakrishnan Geethakumari P, Moyo TK, Sandoval-Sus J, Epperla N, Wallace DS, Kamdar M, Tavarozzi R, Danilov A, Tun H, Munoz J, Narkhede M, Rhodes JM, Prica A, Kuhnl A, Maraj A, Okosun J, Smith J, Osborne W, Calvert V, El-Sharkawi D, Hilali A, Collins GP, Linton K, Elmusharaf N, Santarsieri A, Karim F, Baidoun F, Monick SE, Trutzer IM, Can J, Ayers A, Calabrese De Feo J, Sharp J, Ghosh N, Treitman R, Kallam A, Okcu I, Abeyakoon C, Hann W, Barrett A, Deshani V, Kahl BS, Chavez JC, Olszewski AJ, Cwynarski K. Treatment-related outcomes and patterns of relapse in secondary CNS involvement by large B-cell lymphoma. Blood. 2026 Apr 16; 147(16):1814-1827.
Score: 0.046
-
Iqbal M, Kumar A, Dreger P, Chavez J, Sauter CS, Sureda AM, Bachanova V, Maziarz RT, Dreyling M, Smith SM, Jacobson C, Glass B, Casulo C, Oluwole OO, Montoto S, Advani R, Cohen J, Salles G, Hamad N, Kuruvilla J, Kahl BS, Shadman M, Kanate AS, Budde LE, Kamdar M, Flowers C, Hamadani M, Kharfan-Dabaja MA. Clinical Practice Recommendations for Hematopoietic Cell Transplantation and Cellular Therapies in Follicular Lymphoma: A Collaborative Effort on Behalf of the American Society for Transplantation and Cellular Therapy and the European Society for Blood and Marrow Transplantation. Transplant Cell Ther. 2024 09; 30(9):832-843.
Score: 0.040
-
Crombie JL, Graff T, Falchi L, Karimi YH, Bannerji R, Nastoupil L, Thieblemont C, Ursu R, Bartlett N, Nachar V, Weiss J, Osterson J, Patel K, Brody J, Abramson JS, Lunning M, Shah NN, Ayed A, Kamdar M, Parsons B, Caimi P, Flinn I, Herrera A, Sharman J, McKenna M, Armand P, Kahl B, Smith S, Zelenetz A, Budde LE, Hutchings M, Phillips T, Dickinson M. Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy. Blood. 2024 04 18; 143(16):1565-1575.
Score: 0.040
-
Wang M, Siddiqi T, Gordon LI, Kamdar M, Lunning M, Hirayama AV, Abramson JS, Arnason J, Ghosh N, Mehta A, Andreadis C, Solomon SR, Kostic A, Dehner C, Espinola R, Peng L, Ogasawara K, Chattin A, Eliason L, Palomba ML. Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study. J Clin Oncol. 2024 04 01; 42(10):1146-1157.
Score: 0.039
-
Major A, Yu J, Shukla N, Che Y, Karrison TG, Treitman R, Kamdar MK, Haverkos BM, Godfrey J, Babcook MA, Voorhees TJ, Carlson S, Gaut D, Oliai C, Romancik JT, Winter AM, Hill BT, Bansal R, Villasboas Bisneto JC, Nizamuddin IA, Karmali R, Fitzgerald LA, Stephens DM, Pophali PA, Trabolsi A, Schatz JH, Hu M, Bachanova V, Slade MJ, Singh N, Ahmed N, McGuirk JP, Bishop MR, Riedell PA, Kline J. Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions. Blood Adv. 2023 08 22; 7(16):4528-4538.
Score: 0.038
-
Gouni S, Rosenthal AC, Crombie JL, Ip A, Kamdar MK, Hess B, Feng L, Watson G, Ayers A, Neelapu SS, Khurana A, Lin Y, Iqbal M, Merryman RW, Strati P. A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy. Blood Adv. 2022 05 10; 6(9):2757-2762.
Score: 0.035
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|